Literature DB >> 16409263

Profile of acne patients in the Philippines requiring a second course of oral isotretinoin.

Indra Haryati1, Sylvia S Jacinto.   

Abstract

BACKGROUND: Oral isotretinoin (OI) is currently the gold standard in the treatment of moderately severe to severe acne vulgaris. Approximately 50-85% of patients achieve permanent cure with one course based on 1.0-2.0 mg/kg/body weight. It has been shown that a dosage of less than 1 mg/kg/body weight predisposed to noncure and required a second course for a permanent cure.
OBJECTIVE: Purpose of this study was to describe the profile of acne patients in the Philippines requiring a second course of OI.
METHODS: Charts of acne vulgaris patients given OI in a private dermatology clinic (SSJ) over a period of 10 years were reviewed and analyzed. All patients were given a total dose of 1 mg/kg/body weight (cumulative total dose of 120 mg/kg/body weight). RESULT: Of 240 patients taking OI included in the study, 193 completed the entire course. One hundred and 43 (59.6%) were cured after one course and required no further therapy (control group: CG), 42 (17.5%) experienced relapse and were treated with topical therapy, and eight (3.3%) relapsed and required oral antibiotic plus topical therapy. Only 47 patients (19.6%) required a second course of OI therapy (study group: SG). There was no difference between the two groups in age, sex, severity, and location of lesions. Two factors were found to be of statistically significant difference: Total dose actually taken with 103.5 mg/kg/body weight for the SG vs. 118.55 mg/kg/body weight for the CG. Median duration of treatment was 6.7 months for the SG vs. 7.41 months for the CG, respectively.
CONCLUSION: The profile of acne patients in the Philippines requiring a second course of OI is seen in those taking a mean cumulative dose (actual total dose) less than 120 mg/kg/body weight, with a mean actual duration of 6.7 months.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16409263     DOI: 10.1111/j.1365-4632.2005.02284.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  5 in total

1.  The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions.

Authors:  James J Leyden; James Q Del Rosso; Eric W Baum
Journal:  J Clin Aesthet Dermatol       Date:  2014-02

2.  Face to face with oral isotretinoin: a closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-11

3.  Comparative Pharmacokinetic Profiles of a Novel Low-dose Micronized-isotretinoin 32 mg Formulation and Lidose-isotretinoin 40 mg in Fed and Fasted Conditions: Two Open-label, Randomized, Crossover Studies in Healthy Adult Participants.

Authors:  Sumit Madan; Sudershan Kumar; Jeanett Segal
Journal:  Acta Derm Venereol       Date:  2020-02-05       Impact factor: 3.875

Review 4.  Isotretinoin; A review on the Utilization Pattern in Pregnancy.

Authors:  Sajad Khiali; Afshin Gharekhani; Taher Entezari-Maleki
Journal:  Adv Pharm Bull       Date:  2018-08-29

Review 5.  Comparing the frequency of isotretinoin-induced hair loss at <0.5-mg/kg/d versus ≥0.5-mg/kg/d dosing in acne patients: A systematic review.

Authors:  Yuliya Lytvyn; Katherine McDonald; Asfandyar Mufti; Jennifer Beecker
Journal:  JAAD Int       Date:  2022-02-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.